Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious technique, conolidine modulates alternate molecular targets. A Science Advancements review found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://katherinea912tgt0.wikilima.com/user